Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)
Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%
Amgen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Amgen's operating income for the twelve months ending Sep 30, 2026 was $12.61B, up 45.4% year over year. For fiscal 2025 it was $9.08B, up 25.1% from the year before. Over ten years it grew 0.7% a year on average. The highest annual figure on record is $10.26B in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.08B | +25.1% |
| FY2024 | Dec 31, 2024 | $7.26B | -8.1% |
| FY2023 | Dec 31, 2023 | $7.90B | -17.4% |
| FY2022 | Dec 31, 2022 | $9.57B | +25.2% |
| FY2021 | Dec 31, 2021 | $7.64B | -16.4% |
| FY2020 | Dec 31, 2020 | $9.14B | -5.5% |
| FY2019 | Dec 31, 2019 | $9.67B | -5.7% |
| FY2018 | Dec 31, 2018 | $10.26B | +2.9% |
| FY2017 | Dec 31, 2017 | $9.97B | +1.8% |
| FY2016 | Dec 31, 2016 | $9.79B | +15.6% |
| FY2015 | Dec 31, 2015 | $8.47B | +36.8% |
| FY2014 | Dec 31, 2014 | $6.19B | +5.5% |
| FY2013 | Dec 31, 2013 | $5.87B | +5.2% |
| FY2012 | Dec 31, 2012 | $5.58B | +29.3% |
| FY2011 | Dec 31, 2011 | $4.31B | -22.2% |
| FY2010 | Dec 31, 2010 | $5.55B | +0.7% |
| FY2009 | Dec 31, 2009 | $5.51B | +5.6% |
| FY2008 | Dec 31, 2008 | $5.21B | +31.0% |
| FY2007 | Dec 31, 2007 | $3.98B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.71B | +46.9% |
| Q2 FY2026 | Jun 30, 2026 | $3.51B | +32.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.67B | +126.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.72B | +17.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.53B | +23.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.66B | +39.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.18B | +18.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.31B | +81.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.05B | +1.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.91B | -28.9% |
| Q1 FY2024 | Mar 31, 2024 | $991.00M | -48.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.27B | -43.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.02B | -24.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.68B | +23.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.92B | -23.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.23B | -3.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.66B | +24.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.18B | +8.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.50B | +1.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.30B | -0.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.13B | -9.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.01B | -25.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.45B | -0.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.32B | -2.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.36B | +1.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.68B | -5.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.47B | -9.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.38B | +6.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.32B | -4.8% |
| Q2 FY2018 | Jun 30, 2018 | $2.83B | +5.0% |
| Q1 FY2018 | Mar 31, 2018 | $2.73B | +5.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.25B | -9.7% |
| Q3 FY2017 | Sep 30, 2017 | $2.44B | -3.5% |
| Q2 FY2017 | Jun 30, 2017 | $2.70B | +13.4% |
| Q1 FY2017 | Mar 31, 2017 | $2.59B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.49B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.53B | – |
| Q2 FY2016 | Jun 30, 2016 | $2.38B | – |
See a number that looks wrong?